title: Effectiveness of early chemotherapy treatment in anaplastic astrocytoma patients.
abstract: There are limited data in the literature concerning chemotherapy trials for the treatment of anaplastic astrocytomas. Forty-one anaplastic astrocytoma patients, operated on during the period 1988 to 1993 at the Neurological institute of Milan, received 4-5 cycles of chemotherapy (BCNU + cisplatin), subsequently radiotherapy (median dose 56.5 Gy), and finally a second-line chemotherapy protocol at recurrence (procarbazine, vincristine, lomustine). The aim of the study was to evaluate the effectiveness of the planned protocol, considering the time to tumor progression and the survival time. The group of anaplastic astrocytoma patients was compared with a homogeneous group of 39 anaplastic astrocytoma patients treated only with radiotherapy after surgery. The median time to tumor progression of patients on the protocol was 24.5 months. The median survival time for anaplastic astrocytoma patients treated with our scheduled protocol or only with radiotherapy was 38.8 and 21 months, respectively. However, our data need to be confirmed by large randomized clinical studies.
authors.affiliation: Istituto Nazionale Neurologico C. Besta, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Silvani
authors.forename: A
authors.initials: A
authors.lastname: Salmaggi
authors.forename: A
authors.initials: A
authors.lastname: Pozzi
authors.forename: L
authors.initials: L
authors.lastname: Fariselli
authors.forename: A
authors.initials: A
authors.lastname: Franzini
authors.forename: A
authors.initials: A
authors.lastname: Boiardi
mesh_terms: D000293:Adolescent; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000628:therapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000628:therapy; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011344:Procarbazine / Q000008:administration & dosage; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine